Stanley Lipkowitz

8.4k citations

109 papers · 6.3k indexed · 2 hit papers · h-index 38

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Cancer Research top 2%
- NF-κB Signaling Pathways

Papers in

Cancer Research 27
- NF-κB Signaling Pathways 8
Oncology 48
- Cancer-related Molecular Pathways 18
- PARP inhibition in cancer therapy 14
- HER2/EGFR in Cancer Research 7

Co-authors: Sireesha V. Garimella Kathryn J. Chavez Marion M. Nau Seth A. Ettenberg Allan M. Weissman Maccon Keane E K Russell Ilan R. Kirsch
Journals: Cancer Research (9 papers)PLoS ONE (7 papers)Journal of Biological Chemistry (5 papers)Journal of Clinical Oncology (5 papers)Oncogene (4 papers)
Partner nations: United States Japan China

In The Last Decade

Stanley Lipkowitz

107 papers receiving 6.2k citations

Hit Papers

align trajectories log scale

Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer 2011 · 575 citations

Peers

Countries citing papers authored by Stanley Lipkowitz

Since Specialization

Citations

This map shows the geographic impact of Stanley Lipkowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley Lipkowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley Lipkowitz more than expected).

Fields of papers citing papers by Stanley Lipkowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley Lipkowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley Lipkowitz. The network helps show where Stanley Lipkowitz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stanley Lipkowitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stanley Lipkowitz Line = papers co-authored together Stanley Lipkowitz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	US cancer deaths prevented due to survival improvements stratified by extent of disease, 2010-2019 JNCI Journal of the National Cancer Institute ·Meredith S. Shiels, Neal D. Freedman, Boyke Agung Nugraha, Amy Berrington de González, Stanley Lipkowitz, Douglas R. Lowy, Ruth M. Pfeiffer	2025	1
2	Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer Cancer Gene Therapy ·林琣p, Yoshimi Endo Greer, Teruhiko Yoshida, Brittney S. Harrington, Soumya Korrapati, Yusuke Shibuya, 陈秀莲, Jeffrey B. Kopp, Takeo Fujii, Stanley Lipkowitz, Christina M. Annunziata	2024	6
3	A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma The Oncologist ·Gustave Fradin, Yoshimi Endo Greer, Sarah M. Jenkins, Margaret E. Gatti‐Mays, Nicole Houston, Sunmin Lee, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Tamara Suria Nengsi, Christina M. Annunziata, Jungmin Lee, Kunio Nagashima, Jane B. Trepel, Stanley Lipkowitz, Alexandra S. Zimmer	2023	6
4	Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer Frontiers in Pharmacology ·大吾相内, Eric C. J. M. Heezius, Wimal Pathmasiri, Blake R. Rushing, Natalie K. Barker, Kim N de Jonge, Yuanyuan Li, 敦子荻原, Yoshimi Endo Greer, Laura E. Herring, Stanley Lipkowitz, Susan Sumner, Edwin J. Iwanowicz, Lee M. Graves	2023	13
5	Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis Cancer Research Communications ·Yoshimi Endo Greer, Lídia Hernandez, 大吾相内, 丁玉萍, Donna Voeller, Raj Chari, 晋角田, Thomas S.K. Gilbert, Mai-Lan Ho, Binwu Tang, Markus Hafner, Qingrong Chen, Daoud Meerzaman, Edwin J. Iwanowicz, Christina M. Annunziata, Lee M. Graves, Stanley Lipkowitz	2022	20
6	Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab BMJ Case Reports ·大西通広, Daniel Desmond, John Ellis, Stanley Lipkowitz	2021	3
7	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study Clinical Cancer Research ·Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, E. Hitt Nichols, Mohammadhadi Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, Jung‐Min Lee	2020	150
8	Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Future Oncology ·Alexandra S. Zimmer, Seth M. Steinberg, Dee Dee Smart, Mark R. Gilbert, Terri S. Armstrong, Eric Burton, Nicole Houston, Nadia Biassou, Brunilde Gril, Priscilla K. Brastianos, Scott L. Carter, David Lyden, Stanley Lipkowitz, Patricia S. Steeg	2020	21
9	Cbl interacts with multiple E2s in vitro and in cells PLoS ONE ·Benjamin C.T Field, Ke Ma, Donna Voeller, Philip Ryan, Jinqiu Chen, Rachel E. Klevit, Stanley Lipkowitz	2019	19
10	First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging Journal of Translational Science ·Natalia Gandía Carbonell, Esther Mena, Yolanda McKinney, Karen Wong, Stephen Adler, Tristan M. Sissung, Lorraine Barbara Frater, Stanley Lipkowitz, Liza Lindenberg, Barış Türkbey, Shivaani Kummar, Jillian Downey, Ali Alayan, 森岡由希子, Samah Aslaoui, Donal E Nilsson, Marcos Daniel Renó Faria, 李光聪	2018	13
11	Update on PARP Inhibitors in Breast Cancer Current Treatment Options in Oncology ·Alexandra S. Zimmer, C A JANDA, Stanley Lipkowitz, Jung‐Min Lee	2018	91
12	Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells Molecular Pharmaceutics ·浩三矢嶋, Д. Р. Нурмухаметов, You Ca, James L. Howard, 中央環境審議会石綿健康被害判定小委員会, Michelle L. Bookstaver, Tek N. Lamichhane, Sonja Sokic, Benjamin C.T Field, Maura O’Neill, Þorkell Andrésson, Arif Hussain, Stanley Lipkowitz, Steven M. Jay	2017	25
13	A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa) Annals of Oncology ·Jang‐Ming Lee, Fatima Karzai, Alexandra S. Zimmer, Christina M. Annunziata, Stanley Lipkowitz, Brian Deegan, Nicole Houston, Irene Ekwede, Elise C. Kohn	2016	13
14	Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation Cancer Research ·Minghui Li, Stephen C. Kales, T. K. Poplavskaya, Benjamin A. Shoemaker, Juan Crespo-Barreto, Andrew L. Cangelosi, Stanley Lipkowitz, Anna R. Panchenko	2015	27
15	Molecular Pathways: Cbl Proteins in Tumorigenesis and Antitumor Immunity—Opportunities for Cancer Treatment Clinical Cancer Research ·Benjamin C.T Field, Ke Ma, Stanley Lipkowitz	2014	75
16	Enigma Prevents Cbl-c-Mediated Ubiquitination and Degradation of RETMEN2A PLoS ONE ·Stephen C. Kales, Marion M. Nau, Anand S. Merchant, Stanley Lipkowitz	2014	22
17	E3 Ubiquitin Ligase Cbl-b Suppresses Proallergic T Cell Development and Allergic Airway Inflammation Cell Reports ·Guilin Qiao, Haiyan Ying, Yixia Zhao, Javaid Hafiza Saira, Hui Guo, Mohanbir Singh, Zhenping Li, Julian Solway, Enxiang Tao, Y. Jeffrey Chiang, Stanley Lipkowitz, Josef Penninger, Wallace Y. Langdon, Jian Zhang	2014	50
18	Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer Breast Disease ·Kathryn J. Chavez, Sireesha V. Garimella, Stanley Lipkowitz Hit paper breakdown →	2011	575
19	Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome Breast Cancer Research and Treatment ·Lyndsay M. Murrow, Sireesha V. Garimella, Tamara L. Jones, Natasha J. Caplen, Stanley Lipkowitz	2009	73
20	Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1 Molecular Cell ·Gil Levkowitz, Hadassa Waterman, Seth A. Ettenberg, Menachem Katz, Alexander Y. Tsygankov, Iris Alroy, Sara Lavi, Kazuhiro Iwaï, Yuval Reiss, Aaron Ciechanover, Stanley Lipkowitz, Yosef Yarden Hit paper breakdown →	1999	823

About Stanley Lipkowitz

Stanley Lipkowitz is a scholar working on Cancer Research, Oncology, Reproductive Medicine, Immunology and Molecular Biology, having authored 109 papers that have together received 6.3k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (27 papers), Cell death mechanisms and regulation (19 papers), Cancer-related Molecular Pathways (18 papers), PARP inhibition in cancer therapy (14 papers), Ovarian cancer diagnosis and treatment (10 papers), DNA Repair Mechanisms (8 papers), NF-κB Signaling Pathways (8 papers) and HER2/EGFR in Cancer Research (7 papers). The work is most often cited by research in Oncology (2.4k citations), Cancer Research (1.1k citations), Molecular Biology (4.2k citations), Immunology (1.2k citations) and Cell Biology (596 citations). Stanley Lipkowitz has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Sireesha V. Garimella, Kathryn J. Chavez, Marion M. Nau, Seth A. Ettenberg, Allan M. Weissman, Maccon Keane, E K Russell, Ilan R. Kirsch, Gil Levkowitz and Aaron Ciechanover. Their work appears in journals such as Cancer Research, PLoS ONE, Journal of Biological Chemistry, Journal of Clinical Oncology and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact